The rule, released Thursday, builds on Trump administration’s priorities, including cutting Medicare reimbursement for drugs ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing. The Centers for Medicare & Medicaid Services (CMS) ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

Eli Lilly and Co. has restricted access to its drug discount program for safety-net hospitals, requiring them to submit ...

As the Trump administration prepares to force its Most Favored Nation price controls on drug makers, a major U.S. lobbying group is pushing for a change to drug discounts law that would necessitate a ...